Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. In this presentation, industry and medical representatives including Patrice Hugo, PhD, Chief Scientific Officer, IQVIA Laboratories, discuss their novel and innovative immunotherapy programs which aim to expedite treatment of cancer. Download this presentation to learn more about cancer immunotherapy trials and the future of cancer treatment.
View full presentation here.
Speakers:
Patrice Hugo, CSO, IQVIA Laboratories
Jonathan Cheng, Section Head/PDT Lead SCCHN, GCD Oncology, Merck
Samir Khleif, Director of GRU Cancer Center, Augusta University
Jim Novotny, Group Director, Pharmacodiagnostics, Bristol-Myers Squib
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
MASH and Liver Disease Capabilities
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
